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ABSTRACT
Objective To assess whether use of the antidepressant
venlafaxine is associated with an increased risk of
sudden cardiac death or near death compared with other
commonly used antidepressants.
Design Population based observational study.
Setting We did a nested case-control analysis within a
new user cohort formed using the United Kingdom
General Practice Research Database.
Participants New users of venlafaxine, fluoxetine,
citalopram, or dosulepin on or after 1 January 1995, aged
18 to 89 years, with a diagnosis of depression or anxiety.
Participants were followed-up until February 2005, or the
occurrence of sudden cardiac death or near death,
identifiedfrommedicalrecordsindicatingnon-fatalacute
ventriculartachyarrhythmia,suddendeathduetocardiac
causes, or out of hospital deaths from acute ischaemic
cardiac events. For each case, 30 controls were selected
matched for age, sex, calendar time, and indication. We
used conditional logistic regression to calculate the
adjustedoddsratioofsuddencardiacdeathorneardeath
associatedwithcurrentuseofvenlafaxinecomparedwith
current use of fluoxetine, citalopram or dosulepin.
Results 207384 participants were followed-up for an
average of 3.3 years. There were 568 cases of sudden
cardiac death or near death, which were matched to
14812 controls. The adjusted odds ratio of sudden
cardiac death or near death associated with venlafaxine
use was 0.66 (95% confidence interval 0.38 to 1.14)
relative to fluoxetine use, whereas compared with
citalopram it was 0.89 (0.50 to 1.60) and with dosulepin
0.83 (0.46 to 1.52).
Conclusions In this large, population based study, the
use of venlafaxinewas not associated withan excessrisk
of sudden cardiac death or near death compared with
fluoxetine, dosulepin, or citalopram, in patients with
depression or anxiety.
INTRODUCTION
The safety of antidepressant drugs, particularly the
newer agents, has been the subject of much debate.
The selective serotonin receptor inhibitors (SSRI), as
well as more recent agents such as venlafaxine, a sero-
tonin-norepinephrine reuptake inhibitor (SNRI), have
received special scrutiny from regulators. Although
the greatest attention has focused on the suicide asso-
ciated risks with these agents, three observational stu-
dies conducted in the United Kingdom reported a
higherrateoffataloverdosewithvenlafaxineusecom-
paredwithSSRIs.
1-3Whilethesestudiessuggestedthat
venlafaxine is more toxic in overdose, their design
could not measure or adjust for patient factors that
could also account for this observation, if the drugs
were selectively prescribed to patients with different
underlying risks of suicide.
45
The mechanism of death in patients who died from
venlafaxine overdose has not been well established.
One hypothesis is that venlafaxine promotes haemo-
dynamically significant (herein referred to as malig-
nant) ventricular tachyarrhythmias through ion
channeleffectsthatprolongtheQRSand/orQTinter-
val.Oneinvitrostudyfoundthatvenlafaxineinhibited
thefastsodiumchannelinguineapigmyocytes,butthe
study was not conducted under physiological
conditions.
6 In vivo, QRS prolongation has been
reported in the overdose setting but not seen in rando-
mised controlled trials.
78 Clinically important
increasesintheQTcintervalwereobservedrarelydur-
ing registration trials,
9 in uncontrolled prospective
cohort studies,
10 and in the overdose setting.
1112 No
cases of malignant ventricular arrhythmias were
reported in the pre-registration clinical trials of
venlafaxine,
8 but the studies were not powered to
detect such rare adverse events. Another possible
mechanismthroughwhichvenlafaxinecouldpromote
arrhythmias is by precipitating cardiac ischaemia,
given that the drug can increase blood pressure and
heart rate.
101314
Concerns that venlafaxine was less safe than SSRIs
inpartduetocardiotoxicityledtoregulatoryaction.In
December 2004 the UK Medicines and Healthcare
products Regulatory Agency (MHRA) restricted pre-
scription of venlafaxine to specialists and contraindi-
cated its use in patients with heart disease, electrolyte
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After further review, in May 2006 the MHRA revised
its regulatory position. The new prescribing informa-
tion again allowed prescribing by non-specialists
(except at very high doses) and updated the cardiac
contraindications, advising now that only patients at
veryhighriskofventriculararrhythmiaorwithuncon-
trolled hypertension should not use venlafaxine.
917
However, we know of no systematic study that has
assessed the risk of malignant arrhythmias or sudden
cardiac death associated with the use of venlafaxine in
usual clinical practice.
Wethereforeusedapopulationbasedobservational
approach to assess the risk of out-of-hospital haemo-
dynamically significant acute ventricular tachy-
arrhythmia or sudden cardiac death associated with
venlafaxine use relative to the use of fluoxetine, citalo-
pram,ordosulepininpatientstreatedfordepressionor
anxiety.
METHODS
We did a cohort study with a nested case-control ana-
lysis using data obtained from the United Kingdom
General Practice Research Database (GPRD). This
database contains more than 35 million person years
of data from patient records continuously collected
since 1987. Participating general practices currently
contribute data on more than 3 million patients,
roughly 5% of the UK population. Data collected
included demographics, medical diagnoses, all pre-
scriptions,referralstosecondarycare,andhospitaldis-
charge reports. Participating general practitioners
(GPs)receivetrainingindataentry,andoncepractices
havemetcertainqualitystandards,theyaredeemedas
“up-to-standard.”
18 Diagnoses are recorded using
OXMIS or Read codes.
Study cohort and design
Thestudycohorthaspreviouslybeenusedtoassessthe
risk of suicide in patients treated with venlafaxine.
19
Briefly, it was formed from all new users of venlafax-
ine, fluoxetine, citalopram, or dosulepin on or after 1
January 1995. We defined new users as patients who
had received no prescription of the study drug in the
year before cohort entry. Patients were aged between
18and89yearsonthedateoftheincidentprescription,
and only patients with a clinical record for depression
or anxiety on the date of or at any time before the inci-
dentprescriptionwereselected.Patientswereincluded
inthecohortiftheyhadapermanentregistrationstatus
with a participating general practice, had at least a one
year longitudinal record before the incident prescrip-
tion, had an acceptable patient status for data quality,
andoriginatedfromageneralpracticewhichwasupto
standard for at least a year before the incident
prescription.
20Patientswithahistoryoflifethreatening
ventricular tachyarrhythmia, cardioversion, aborted
cardiacarrest,orimplantationofacardiacdefibrillator
beforecohortentrywereexcluded.Patientswithacon-
genital conduction disorder or advanced cardio-
myopathy (hypertrophic or dilated) before cohort
entry or at any time during follow-up were also
excluded.
Patients were followed-up over time from their inci-
dent prescription date (cohort entry) until the earliest
ofoccurrenceofthestudyoutcome,death,transferout
of practice, or the practice’s last collection date before
February 2005, when data for this study were extra-
cted. We used a case-control analysis nested within
the cohort to deal with the complex time-varying nat-
ure of antidepressant use.
2122
Case definition
Theunifyingfeatureofourcompositeoutcomeofsud-
dencardiacdeathorneardeathwastheoccurrenceofa
malignant ventricular tachyarrhythmia, which typi-
cally occurs in the presence of coronary atherosclero-
sis, its complications, or other structural heart
disease.
23 For near deaths, the occurrence of such a
tachyarrhythmia was well documented and supported
by the report of symptoms of presyncope or syncope
before or during the event and/or the necessity of
emergent cardioversion. For individuals who died,
the tachyarrhythmia was often presumed because
Antidepressant study cohort (n=207 384)
Event date after end
of follow-up (n=103)
Event date after end
  of follow-up plus
  2 weeks (n=8)
Included in sudden
  death (n=52)
Definitely not an event
  (supraventricular
  tachycardia n=92,
  other n=37)
Probably not an event
  (n=26)
Definitely an event but
  not meeting some
  inclusion criteria (n=18)
Definitely an event but
  insufficient information
  on inclusion criteria
  (n=12)
Possible event, cannot
  be ruled out because
  of insufficient
  information (n=11)
Terminal illness (n=29)
Acute event (n=86)
Suicide (n=18)
Decompensated
  congestive heart
  failure (n=3)
Other (n=49)
Terminal illness (n=18)
Acute event (n=46)
Decompensated
  congestive heart
  failure (n=7)
Hospital or nursing home
  death (n=150)
Other acute cause of
  death (n=113)
Hospital or nursing home
  death (n=32)
Other acute cause of
  death (n=58)
Event date after end
  of follow-up plus
  2 weeks (n=409)
Patient is alive (n=1070)
Cohort subject with Read code
or free text for acute ventricular
 tachyarrhythmia (n=326)
Cohort subject with Read code
or free text for sudden death
(n=1990)
Sudden death events during
study period (n=511)
IHD death during
study period (n=639)
Sudden death possible cases
for manual review (n=421)
Acute ventricular
tachyarrhythmia possible cases
for manual review (n=223)
IHD possible cases for
manual review (n=376)
Sudden cardiac
death (n= 236)
Acute ventricular
tachyarrhythmia (n= 27)
Cardiac ischaemic
deaths (n= 305)
Cohort subject with ischaemic
heart disease (IHD) recorded
within one day of death (n=699)
Flowchart of case ascertainment
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sourcesofoutofhospitalcaseswereidentified:patients
withnon-fatalbut haemodynamically significant acute
ventricular tachyarrhythmia; patients with a record of
suddendeathduetocardiaccausesischaemicorother-
wise; and patients seeming to have died out of hospital
from an acute ischaemic cardiac event that was not
necessarily labelled as sudden.
First, potential cases of acute ventricular tachyar-
rhythmia were identified from Read or OXMIS
codes and word strings in the free text comments of
GPs, in which case the complete de-identified free
text was obtained from the GPRD. This text was
reviewedbyoneoftheauthors(CM),blindedtoexpo-
sure status, to assess whether additional chart informa-
tion should be requested from the GP to clarify if the
outcome of interest had occurred. The complete clin-
ical profile of all these potential acute ventricular
tachyarrhythmia cases was independently reviewed
by two authors (CM and TA), who classified them as
definite or not, and any discordance was resolved by
consensus after further review and discussion. Then,
sudden cardiac death cases were identified from
Read/OXMIS code for “sudden death” or a word
string in a free text comment that suggested the occur-
rence of a sudden death. Death certificates were
obtained from the Office for National Statistics for
England and Wales or the General Register Office for
Scotland and Northern Ireland for the subset of those
individuals who did not have a Read/OXMIS code or
afreetextcommentthatclearlystatedacauseofdeath.
Finally, people dying in the community from an acute
cardiac ischaemic event that was not necessarily
labelled as sudden formed the third group of potential
cases, identified by scanning the Read/OXMIS codes
for a code of ischaemic heart disease or myocardial
infarction on the date of death (plus or minus one
day). The complete profile of all potential sudden car-
diac deaths and acute cardiac ischaemic deaths was
subjected to a computer algorithm that identified and
excluded deaths occurring either in hospital or in nur-
sing homes and deaths apparently due to non-cardiac
pathology.Thisalgorithmwasoptimisedaftercompar-
ingtheresultsoftheinitialrunofthealgorithmwiththe
results of a manual review of a random set of 50 poten-
tial sudden death cases by two authors (CM and TA).
Allpotential casesnotexcludedby the optimised com-
puter algorithm then underwent a manual review by
one of the authors (CM) to further exclude cases that
did not meet all inclusion and exclusion criteria.
Thedefiniteacuteventriculartachyarrhythmia,sud-
den cardiac death, and acute ischaemic cardiac death
cases were combined toform the seriesof cases of sud-
den cardiac death or near death. The date of occur-
rence was designated the index date of the case.
Control selection
For each case we randomly selected up to 30 controls
from the cohort. These controls were matched on
cohort entry date (date of incident prescription plus
or minus 6 months), year of birth, sex, and indication
(depression and/or anxiety). Additionally, controls
had to be at risk of the event on the case’s index date.
Thus, the control’s index date was defined as the date
that corresponded to the same follow-up time as its
matchedcase.Whenfewerthan30controlswereavail-
able for a given case, we relaxed the matching criteria
for cohort entry to within one year. If after this step, a
given case had fewer than 30 controls, all available
individuals were used.
Antidepressant drug exposure
Foreachcaseandtheirmatchedcontrols,weextracted
all prescription records for the study drugs and all
other antidepressants before the index date. We calcu-
lated the duration of each prescription, starting with
thelastprescriptionpriortoindexdate, fromthenum-
ber of tablets prescribed combined with the dosing
instructions. When we were unable to derive duration
of exposure from the available information we
assumed a prescription length of 28 days. For unu-
sually low or high values of prescription length, we
assigned a minimum of seven days and a maximum of
90 days to the prescription length. These assumptions
are based on current prescribing practices in the UK.
We defined current exposure to treatment by a pre-
scription whose duration included the index date. As
Table 1 |Characteristics of cases and controls in the year
before index date. Data are frequencies (percentages) unless
otherwise stated. Percentages cannot be calculated directly
from the corresponding frequencies as they are weighted by
the number of controls matched to each case.
Cases
(n=568)
Controls
(n=14 812)
Age at index date, mean (SD)* 72.9 (12.7) 72.9 (12.8)
Men (%)* 258 (45.4) 6404 (45.4)
Indication for cohort entry
antidepressant*
Depression 455 (80.1) 12893 (80.1)
Anxiety 87 (15.3) 1594 (15.3)
Both 26 (4.6) 325 (4.6)
Obesity status
Obese (BMI ≥30) 86 (15.1) 2093 (13.4)
Non-obese (BMI <30) 372 (65.5) 10818 (73.3)
Missing information 110 (19.4) 1901 (13.3)
Smoking status
Smoker 249 (43.8) 5565 (37.3)
Non-smoker 239 (42.1) 7429 (50.3)
Missing information 80 (14.1) 1818 (12.5)
Alcohol abuse 16 (2.8) 139 (1.0)
Depression/anxiety
Depression 135 (23.8) 3751 (23.8)
Severe 11 (1.9) 333 (2.1)
Moderate 39 (6.9) 1372 (8.7)
Mild 85 (15.0) 2046 (13.0)
Anxiety 27 (4.8) 668 (5.3)
Both 35 (6.2) 771 (5.2)
None 371 (65.3) 9622 (65.7)
Suicide attempt 5 (0.9) 59 (0.4)
*Matching factors.
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“no use” the absence of prescriptions of a given drug
during the year prior to the index date. Patients with
prescriptions for a given drug during the year before
the index date, but not current users, were classified as
past users.
Covariates
Risk factors for the outcome were identified from
patients’ records in the GPRD. In particular, we iden-
tifieddepression relatedfactors(alcoholabuse,suicide
attempt,depressionseverity),
24cardiovascularriskfac-
tors(obesity,smoking,diabetes,leftventricularhyper-
trophy, hyperlipidaemia, hypertension, rheumatoid
arthritis), cardiovascular diagnoses (acute myocardial
infarction, coronary artery bypass graft and percuta-
neous coronary artery procedures, intraventricular
conduction delay, supraventricular arrhythmia, atrial
arrhythmia, coronary artery disease, angina, conges-
tiveheartfailure,ischaemicstroke,transientischaemic
attack, peripheral vascular disease), other conditions
that have been associated with an increased risk for
sudden cardiac death (epilepsy and schizophrenia),
and conditions or use of drugs that could prolong the
QTinterval,includinghypokalaemia,hypomagnesae-
mia, and conduction disorders.
2526 We also measured
use of certain classes of drug including non-steroidal
anti-inflammatory drugs (NSAIDs), antipsychotics,
benzodiazepines, mood stabilisers, antiarrhythmic
agents, lipid regulating drugs, and loop diuretics.
Lastly, we identified individuals who had switched
antidepressants between the time of cohort entry and
theindexdate.Exceptforobesity,whichwedefinedas
a body mass index (BMI) of more than 30, covariates
were ascertained from diagnoses, lifestyle factors, or
prescriptions as they appeared in the medical record.
Data analysis
Weusedconditionallogisticregressiontocomputethe
odds ratio of sudden cardiac death or near death, and
its 95% confidence interval, associated with current
exclusive use of venlafaxine compared with current
exclusive use of each of the three other study drugs,
as well as compared with the three drugs as one
group. In a nested case-control study such as ours, the
odds ratio provides an unbiased estimate of the rate
ratio in the cohort.
27
Because the number of controls matched to each
case was variable and to allow unbiased comparisons
betweencasesandcontrols,descriptivestatisticsforthe
characteristics of the controls were weighted by the
inverse of the number of controls in each matched
set, a procedure equivalent to standardising the num-
berofcontrolstoonecontrolpercase.Aftertabulating
the data, we performed crude regression analyses. All
analyseswere then adjustedforcomorbidityand other
covariates measured 366-730 days before the index
date,toavoidadjustingforfactorsaffectedbyexposure
during the year prior to the index date. We also
assessed the effect of duration of exposure in patients
currently exposed to the study drugs.
We performed several sensitivity analyses. We
repeated the main analyses after restricting our out-
come to the first two sources of cases (non-fatal acute
ventricular tachyarrhythmia as well as sudden deaths
due to any cardiac pathology). We repeated the main
analyses adding a lag of 15 days to the end of the pre-
scription duration, to allow for possible late exposures
beyond the prescription duration. We repeated the
main analyses using two alternative time periods in
which covariates were measured. We first adjusted
for comorbidities measured in the year beginning
415 days before the index date, instead of the year
beginning 730 days before the index date, and then
adjustedonlyforcovariatesascertainedpriortocohort
entry, to address any concerns about adjusting for fac-
tors that were actually drug effects. We also restricted
the covariates to those that affected the odds ratio by
10% or more. Finally, to assess effect modification, the
estimates were stratified by the indication for the anti-
depressant,bythepresenceorabsenceofadiagnosisof
myocardialinfarctionbeforetheindexdate,andbythe
occurrence of switching among antidepressant classes
Table 2 |Cardiovascular comorbidity of cases and controls
before index date. Data are frequencies (percentages) unless
otherwise stated. Percentages cannot be calculated directly
from the corresponding frequencies as they are weighted by
the number of controls matched to each case.
Cases
(n=568)
Controls
(n=14 812)
In 2 years before index date
Acute myocardial infarction before
index date (%)
0-3 months 14 (2.5) 28 (0.2)
3-6 months 7 (1.2) 27 (0.2)
6-12 months 10 (1.8) 57 (0.4)
12-15 months 6 (1.1) 29 (0.2)
15-18 months 1 (0.2) 28 (0.2)
18-24 months 2 (0.4) 62 (0.5)
In the year before the year before index date
Cardiac revascularisation 1 (0.2) 47 (0.3)
Intraventricular conduction delay 0 (0.0) 0 (0.0)
Supraventricular arrhythmia 29 (5.1) 234 (1.6)
Left ventricular hypertrophy 2 (0.4) 8 (0.1)
Coronary artery disease and angina 39 (6.9) 628 (4.3)
Congestive heart failure (CHF) 51 (9.0) 368 (2.5)
Severe CHF* 37 (6.5) 256 (1.7)
Ischaemic stroke 9 (1.6) 199 (1.5)
Transient ischaemic attack 6 (1.1) 204 (1.5)
Diabetes 78 (13.7) 791 (5.0)
Peripheral vascular disease 11 (1.9) 166 (1.2)
Hyperlipidaemia 7 (1.2) 198 (1.4)
Hypertension 38 (6.7) 799 (5.4)
Hypokalaemia 4 (0.7) 39 (0.3)
Hypomagnesaemia 0 (0.0) 0 (0.0)
Conduction disorder 1 (0.2) 5 (0.03)
*Severe CHF defined by presence of a diagnosis for decompensated CHF
or by any CHF diagnosis followed by a prescription of a loop diuretic
within 3 months.
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We used SAS v9.1. (Cary, NC, USA) statistical soft-
wareforallanalyses.Thestudyprotocolwasapproved
bytheIndependentScientificAdvisoryCommitteefor
GPRD research, and this report includes all relevant
STROBE elements.
RESULTS
Theinitialcohortincluded269084individualswithan
incident prescription of one of the study drugs after
January 1995 and with at least a year of data prior to
that prescription. We then excluded 2426 patients
because they were younger than 18 years or older
than 90 at the date of the incident prescription;
58464 patients without a diagnosis of depression or
anxiety before or concurrent with the incident pre-
scription; 473 patients with congenital conduction dis-
order, cardiomyopathy, or history of acute ventricular
tachyarrhythmia;284patientswithcardioversion,car-
diac arrest with resuscitation, or implantation of an
internal cardiac defibrillator prior to cohort entry;
and 53 patients with incomplete follow-up informa-
tion. Thus, the final study cohort consisted of 207384
first time users of venlafaxine (n=19268), citalopram
(n=53300), fluoxetine (n=90924), or dosulepin (n=
43892). Over the study period, 17783 patients who
entered the study taking one of the comparator anti-
depressants were subsequently prescribed venlafax-
ine, bringing the total number of individuals exposed
to venlafaxine to 35051.
The mean age at cohort entry was 46 years, with a
mean of 7.8 years of available data in the practice
between the time it was deemed up to standard for
data collection purposes and cohort entry and a mean
follow-upof3.3years.Athirdofcohortmemberswere
men. The diagnosis associated with antidepressant use
wasdepressionin84%andanxietyin16%.Almosthalf
of the patients had never been prescribed any other
antidepressant before the qualifying prescription.
Compared with patients initiating fluoxetine, citalo-
pram, or dosulepin, patients initiating venlafaxine
were more likely to have previously used tricyclics,
SSRIs, monamine oxidase inhibitors, or other anti-
depressants (supplemental table 1, see webextras).
They also were more likely to have had more severe
depressionorattemptedsuicide(supplementaltable 2).
Patients initiating venlafaxine were no different in
terms of their cardiovascular comorbidities at baseline
but had greater use of antipsychotic drugs, benzodia-
zepines, and mood stabilisers, as well as somewhat
higher use of drugs that may prolong the QT interval
(supplemental tables 3-4).
The figure 1 describes the algorithm to identify the
threesetsofoutofhospitalcases.Usingthisalgorithm,
we identified 568 cases, including 27 acute ventricular
tachyarrhythmias,236suddencardiacdeaths,and305
out of hospital cardiac ischaemic deaths. The initial
concordance rate regarding case status between the
two authors after their manual review of all potential
acute ventricular tachyarrhythmia and of the random
set of 50 potential sudden death cases was 73%, and all
disagreements were resolved after discussion.
The overall rate of sudden cardiac death or near
death was 8.21 per 10000 person-years. The 568
cases were matched to 14812 controls, with a mean
age of 73 years at the index date. Cases were more
likely to be smokers, to abuse alcohol, and to have
attempted suicide, despite no major differences in the
severityofdepression(table 1).Intheyearpriortothe
yearbeforetheindexdate,casesgenerallyhadahigher
prevalenceofcardiovascularrelatedcomorbidity,par-
ticularlydiabetes,acutemyocardialinfarction,conges-
tiveheartfailure,andatrialarrhythmia(table 2).Cases
also had a higher prevalence of rheumatoid arthritis,
epilepsy,and schizophrenia,aswell asuse ofNSAIDs,
benzodiazepines, lipid regulating agents, loop diure-
tics, and drugs that may prolong the QT interval
(table 3). Although all patients were exposed to one
of the study drugs at cohort entry, over time many
did not continue on these treatments, as would be
expected in clinical practice. On the index date only
a subset of cases (n=155) and controls (n=3916) were
currently exposed to a study drug.
Current venlafaxine use was not associated with an
increased risk of sudden cardiac death or near death
compared with current use of fluoxetine, citalopram,
and dosulepin, with all point estimates of the adjusted
odds ratio less than 1 (table 4, model 1). In an alterna-
tive model that included only covariates that were
measured before cohort entry, results were essentially
the same (table 4, model 2). Stratified analyses did not
show any significant variations in risk by duration of
Table 3 |Comorbidity and drug use of cases and controls in
the year before the year before index date. Data are
frequencies (percentages) unless otherwise stated.
Percentages cannot be calculated directly from the
corresponding frequencies as they are weighted by the
number of controls matched to each case
Cases
(n=568)
Controls
(n=14 812)
Non-cardiovascular comorbidity
Rheumatoid arthritis 4 (0.7) 72 (0.5)
Epilepsy 4 (0.7) 68 (0.5)
Schizophrenia 3 (0.5) 10 (0.1)
Drug use
NSAIDs 273 (48.1) 6443 (43.7)
Antipsychotics 83 (14.6) 1840 (12.9)
Benzodiazepines 181 (31.9) 3582 (25.4)
Mood stabilisers 26 (4.6) 573 (3.8)
Antiarrhythmics 17 (3.0) 270 (1.8)
Lipid regulating drugs 65 (11.4) 1171 (7.8)
Loop diuretics 151 (26.6) 1860 (13.4)
Drugs with potential effect on QT prolongation*
Strong evidence 172 (30.3) 3494 (23.6)
Soft evidence 87 (15.3) 1820 (12.3)
NSAID=non-steroidal anti-inflammatory drugs.
*Prescribed drugs associated with QT prolongation were stratified into
two groups based on the strength of evidence supporting the drug’s
propensity to prolong the QT interval.
22,23
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cohort (table 5).
Sensitivity analyses restricting our outcome to acute
ventriculartachyarrhythmiaandsuddencardiacdeath
did not change the results, nor did adding a lag of
15daystotheendoftheprescriptionduration(supple-
mental tables 5-6). Varying the time window to define
covariatesoradjustingonlyforcovariatesthatchanged
the odds ratio by at least 10% also did not materially
affecttheresults(supplementaltable 7).Finally,results
were similar in models restricted to patients with a
diagnosis of depression as indication for the drugs or
among patients with no diagnosis of acute myocardial
infarctionbeforetheindexdate(supplementaltables 8-
9). Switching from the antidepressant used at cohort
entry to the one at index date was not associated with
anincreasedriskofourcompositeoutcome(oddsratio
0.83; 95% confidence interval 0.52 to 1.32). In an ana-
lysis of switching stratified by each study drug, the
results did not change although the numbers were
small (supplemental tables 10).
DISCUSSION
In this large population based cohort study of patients
treated for depression or anxiety, we found no evi-
dencethatvenlafaxineusewasassociatedwithahigher
risk of out of hospital haemodynamically significant
acute ventricular tachyarrhythmia or sudden cardiac
death compared with the risk observed in fluoxetine,
citalopram, or dosulepin users. While only 18 cases of
sudden cardiac death or near death occurred in
patients currently exposed to venlafaxine, the study
allows us reasonably to exclude odds ratios higher
than 1.14 compared with current fluoxetine use, 1.60
comparedwithcurrentcitalopramuse,1.52compared
with current dosulepin use, and 1.30 compared with
current use of any of the three comparators, based on
the upper bound of the 95% confidence interval for
each of the four comparisons. We also found no com-
pelling evidence that venlafaxine was preferentially
prescribed to patients with lower risk for cardiac
events,consistentwiththeobservationthatadjustment
for potential confounders had minimal effect on
results.
Comparison with other studies
The motivation for this investigation arose from three
recentobservationalstudiesthatreportedahigherrate
of fatal antidepressant overdose with venlafaxine use
compared with SSRIs.
1-3 While one interpretation of
these findings is that venlafaxine is relatively more
toxic in overdose, patient factors rather than differen-
tial drug effects could also explain the phenomenon.
None of these studies adjusted for potential confound-
ing factors, and in fact a UK based utilisation study
demonstrated that venlafaxine was preferentially pre-
scribed to patients with a higher prevalence of risk fac-
tors for suicide.
28 The cause of venlafaxine overdose
deaths has not been well characterised, although a
cardiotoxic mechanism, mediated through malignant
ventricular tachyarrhythmias, has been suggested.
6
The current study assessed the risk of malignant ven-
tricular tachyarrhythmias and sudden cardiac death
among patients receiving venlafaxine and comparator
antidepressants at pharmacological doses, and found
no such association.
Whilesomestudiescomparecurrentuseofadrugto
non-use to assess drug risk, we chose to compare cur-
rent use of one drug to another drug. We believe that
this approach is clinically sensible and minimises con-
founding by indication. We designed the study to
address the following question a clinician might ask
him or herself: “Given that I have chosen to treat my
patientwithanantidepressant,willthechoiceofvenla-
faxine instead of other antidepressants increase my
patient’s risk of unexpected cardiac death or life threa-
tening ventricular tachyarrhythmia?” Alternatively,
one could compare current use to distant past use, but
such an approach could be vulnerable to confounding
by indication. Several studies have suggested that
depressed individuals are at increased risk for cardiac
mortality compared with non-depressed
individuals.
29-32 Less clear is whether depression asso-
ciated risk of adverse cardiovascular outcomes attenu-
ates when depression abates. If this is the case, an
Table 4 |Crude and adjusted odds ratios of sudden cardiac death or near death associated with current use of venlafaxine
relative to current fluoxetine, citalopram, and dosulepin use
Cases
(n=568)
Controls
(n=14 812) Crude odds ratio
Adjusted odds ratio
Model 1* (95% CI)
Adjusted odds ratio
Model 2† (95% CI)
Venlafaxine 18 (3.2) 544 (3. 7)
Versus fluoxetine 63 (11.1) 1281 (8.6) 0.65 0.66 (0.38 to 1.14) 0.66 (0.38 to 1.14)
Versus citalopram 39 (6.9) 1079 (7.3) 0.90 0.89 (0.50 to 1.60) 0.88 (0.49 to 1.56)
Versus dosulepin 35 (6.2) 1012 (6.8) 0.99 0.83 (0.46 to 1.52) 0.86 (0.48 to 1.56).
Versus any of the three 137 (24.1) 3372 (22.8) 0.81 0.77 (0.46 to 1.30) 0.78 (0.47 to 1.29)
*Model 1 adjusted for BMI≥30, smoking status, alcohol abuse, depression severity, suicide attempt, diabetes, coronary artery bypass graft and
endoscopic cardiac procedures, supraventricular arrhythmias, left ventricular hypertrophy, coronary artery disease and angina, congestive heart
failure, severe congestive heart failure, ischaemic stroke, transient ischaemic attack, peripheral vascular disease, hyperlipidaemia, hypertension,
hypokalaemia, rheumatoid arthritis, epilepsy, schizophrenia, use of antipsychotics, benzodiazepine, mood stabilisers, antiarrhythmics, drugs with
some evidence of prolonging QT, drugs with stronger evidence of prolonging QT, lipid regulating drugs, loop diuretics—all ascertained in the year
prior to the year before index date and acute myocardial infarction in the year before index date.
†Adjusted for all factors listed for model 1 as ascertained before cohort entry. Models 1 and 2 included non-users and past users, in addition to
current users. Because the contrasts here are limited to current users, drug specific counts of cases and controls do not add up to column totals.
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antidepressant use with distant past use could easily
be a consequence of confounding by time dependent
patient factors associated with depression itself. Thus,
we selected threeother antidepressant agentsto define
the comparison group, namely fluoxetine, citalopram,
and dosulepin, as in a previous study of suicide risk
associated with venlafaxine that used the same
dataset.
19 Fluoxetine, an SSRI, and dosulepin,a tricyc-
licantidepressant,wereselectedbecausetheywerethe
most commonly prescribed drugs within their respec-
tiveclassesduringthe studyperiod.Ascitalopramand
venlafaxine were introduced in the same year, we
assumed that doctors would preferentially prescribe
both agents to patients who were unresponsive to pre-
viouslyavailabletherapies.
5Tothedegreethatseverity
of depression could increase risk of cardiac events,
29
we believed that selecting citalopram as a comparator
would minimise confounding by disease severity.
Like other antidepressants of the tricyclic class,
dosulepin in the overdose setting can produce malig-
nant arrhythmias, some fatal.
3334 We identified only
one population based study that evaluated the risk of
sudden cardiac death involving tricyclic anti-
depressants at pharmacologic doses.
35 This study
found that, compared with non-use of antidepressants,
tricyclic antidepressants were not associated with an
increased risk of sudden cardiac death at doses of less
than 100 mg per day of amitriptyline equivalents. An
increasedrisk,however,wasobservedat higherdoses.
OurGPRDstudydidnotsuggestanexcessriskofsud-
den cardiac death or near death associated with dosu-
lepin use. We suspect that the relatively infrequentuse
at higher doses may explain this finding. Among
patients currently exposed to dosulepin on the index
date for whom a daily dose could be measured, 87.6%
(840/959) were prescribed less than 100 mg/day (we
assumethatamitriptylineanddosulepinareequivalent
on a mg/mg basis).
36
Limitations of study
Ourstudyhassomelimitations,mostofwhichinvolve
thelevelofdetailintheGPRDmedicalhistoryandthe
challenge of determining the precise sequence of
events in patients who died out of hospital. Firstly, we
couldnotapplystandardiseddefinitionsofsuddencar-
diac death such as those used in large clinical trials,
since we lacked access to complete medical records
and the ability to interview family members of
deceased people. However, our definition of sudden
cardiac death was largely consistent with the one used
in a recent study of antipsychotic drug use and sudden
cardiac death, although ours also included cases of life
threatening but non-fatal ventricular arrhythmias.
37
Secondly, we cannot be certain that all of the fatal
casesincludedinthisstudyhadamalignantventricular
tachyarrhythmia as the final cardiac event before
death. In large part, this limitation is a consequence
of most fatal cases both not being on an electrocardio-
graph at the time of haemodynamic collapse and not
subsequently undergoing autopsy. Furthermore, we
did not have access to medical records detailing the
cardiac rhythm before death in the few cases whose
arrest was witnessed and managed by paramedics or
doctors.Communitystudiessuggestthatsomepatients
who die shortly after haemodynamic collapse from a
cardiac cause may not go through a phase of ventricu-
lar tachyarrhythmia or fibrillation before death.
3839
Nevertheless, we suspect that among cases who did
not have a malignant tachyarrhythmia, most died
from some cardiac cause. To the degree that this
occurred, it is reassuring that venlafaxine was not
Table 5 |Crude and adjusted rate ratios of sudden cardiac death or near death associated with current use of venlafaxine,
fluoxetine, citalopram, and dosulepin, comparing longer with shorter duration of current use. Data are number (percentage)
unless otherwise specified
Cases (n=568) Controls (n=14 812) Crude odds ratio Adjusted odds ratio* (95% CI)
Venlafaxine
<90 days 2 (0.4) 70 (0.5) 1.00 1.32 (0.26 to 6.70)
≥90 days 16 (2.8) 474 (3.2) 1.00 (reference) 1.00 (reference)
Fluoxetine
<90 days 8 (1.4) 261 (1.8) 0.61 0.70 (0.25 to 1.93)
≥90 days 55 (9.7) 1020 (6. 9) 1.00 (reference) 1.00 (reference)
Citalopram
<90 days 8 (1.4) 153 (1.0) 1.94 1.81 (0.63 to 5.21)
≥90 days 31 (5.5) 926 (6. 3) 1.00 (reference) 1.00 (reference)
Dosulepin
<90 days 8 (1.4) 207 (1.4) 1.27 1.44 (0.50 to 4.16)
≥90 days 27 (4.8) 805 (5.4) 1.00 (reference) 1.00 (reference)
*Adjusted for BMI≥30, smoking status, alcohol abuse, depression severity, suicide attempt, diabetes, coronary artery bypass graft and endoscopic
coronary artery procedures, supraventricular arrhythmias, left ventricular hypertrophy, coronary artery disease and angina, congestive heart failure,
severe congestive heart failure, ischaemic stroke, transient ischaemic attack, peripheral vascular disease, hyperlipidaemia, hypertension,
hypokalaemia, rheumatoid arthritis, epilepsy, schizophrenia, use of antipsychotics, benzodiazepine, mood stabilisers, antiarrhythmics, drugs with
some evidence of prolonging QT, drugs with stronger evidence of prolonging QT, lipid regulating drugs, loop diuretics all in the year prior to the year
before index date and acute myocardial infarction in the year prior index date. Because the contrasts here are limited to current users, drug specific
counts of cases and controls do not sum to column totals.
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cardiac causes. Our study reproduced several estab-
lished risk factors of sudden cardiac death,
23 such as
severe congestive heart failure (odds ratio 1.7), recent
acute myocardial infarction (odds ratio 13.4), and left
ventricular hypertrophy (odds ratio 5.9); and it found
anincidencerateofsuddencardiacdeathorneardeath
consistent with the rates of ventricular tachycardia
observedinothercohorts.
40-44Theseobservationssup-
port the validity of our outcome measure despite
incomplete clinical details for many of our cases.
45
Thirdly, although we adjusted our analysis for a com-
prehensive listof potential risk factors forthe outcome
based on the information available in the GPRD, this
adjustmentmightbeincomplete.Sometraditionalrisk
factors of coronary artery disease such as left ventricu-
lar hypertrophy, diabetes, hypertension, and hyperli-
pidaemia appeared to be incompletely captured by
physiciandiagnosesgiventhelowerthanexpectedpre-
valenceoftheseconditions.Furthermore,althoughwe
adjustedforcoronaryarterydiseaseriskfactors,coron-
aryarterydisease,myocardialinfarction,orleftventri-
cular dysfunction, we could not adjust for the age of
onsetandseverityofcoronarydiseaseriskfactors,bur-
den and location of coronary atherosclerosis, location
and size of previous myocardial infarction, or the left
ventricular ejection function as measured on an echo-
cardiogram. We cannot exclude the possibility that
patients with more extensive cardiac disease and con-
sequently a higher risk of malignant arrhythmias were
less likely to have been prescribed venlafaxine. How-
ever,thedistributionofcardiaccomorbiditiesandcor-
onary artery disease risk factors across the four groups
of antidepressant users at study entry does not suggest
that such channelling occurred (supplemental tables 2
and 3). Finally, we cannot exclude the possibility of
exposure misclassification, which could have varied
by study drug. Clinical trial data indicate that patients
receiving venlafaxine discontinue therapy because of
undesirable side effects more often than those receiv-
ing SSRIs.
46 Our GPRD study used prescription data
as a proxy for antidepressant exposure and did not
measure actual drug adherence.
Conclusion
In this large UK population based study in patients
with depression or anxiety, venlafaxine was not asso-
ciated with any excess risk of malignant ventricular
tachyarrhythmia or sudden cardiac death when com-
pared with fluoxetine, dosulepin, or citalopram.
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